Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) on Thursday announced the launch of Prucalopride Tablets, a generic version of Motegrity.

The US Food and Drug Administration (FDA) has granted ANI 180-day marketing exclusivity for its Prucalopride Tablets.

This launch follows the FDA's approval of ANI's Abbreviated New Drug Application (ANDA).

ANI's Prucalopride Tablets are expected to compete in a market with approximately USD168m in annual sales.